Novocure Ltd Stock
€10.25
Your prediction
Novocure Ltd Stock
Pros and Cons of Novocure Ltd in the next few years
Pros
Cons
Performance of Novocure Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novocure Ltd | -2.910% | -25.563% | -31.069% | -40.390% | -64.801% | -85.382% | -82.199% |
Ironwood Pharmaceuticals | -5.480% | 5.344% | 9.524% | -89.048% | -83.571% | -94.009% | -91.737% |
Iovance Biotherapeutics Inc. | -2.050% | 38.378% | 74.744% | -69.379% | -61.468% | -76.981% | -88.880% |
Arrowhead Pharmaceuticals Inc. | -1.700% | -6.940% | -0.149% | -49.719% | -27.494% | -67.104% | -66.234% |
News

Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable

Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and